Harnessing Synapse for Colchicine Information: Strategies and Tips

Takeda Pharmaceutical's approval of colchicine in January 1995 marked a significant milestone in the world of medicine. This small molecule drug belongs to the esteemed class of tubulin polymerization inhibitors, impeding the formation of microtubules in cells. This therapeutic mechanism has proven especially beneficial in treating a range of ailments, including gout, familial Mediterranean fever, and pericarditis. By hindering the movement of neutrophils, cells central to inflammation during these conditions, colchicine efficiently diminishes pain and swelling in affected joints and other tissues. Despite its merits, colchicine has some potential side effects, such as gastrointestinal distress and muscular weakness, which may be more pronounced at higher doses. Nevertheless, colchicine remains a crucial remedy for various inflammatory conditions. Click on the image below to begin the exploration journey of Colchicine through the Synapse database!

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!